ESSENCE Phase 3 trial results demonstrating statistically significant and superior improvements with semaglutide 2.4 mg in people with MASH presented at AASLD 2024 - The Liver Meeting®

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to USD 29.8 billion in the first nine months of 2024

New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight